Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity

References

• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465. doi:10.1056/NEJMoa1200694. PMID:22658128.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–144. doi:10.1056/NEJMoa1305133. PMID:23724846.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030. doi:10.1200/JCO.2013.53.0105. PMID:24590637.
   PubMed Web of Science ®Google Scholar
• Araki K, Youngblood B, Ahmed R. Programmed cell death 1-directed immunotherapy for enhancing T-cell function. Cold Spring Harb Symp Quan Biol. 2014. doi:10.1101/sqb.78.019869. PMID:24415643.
   Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–571. doi:10.1038/nature13954. PMID:25428505.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930–2940. doi:10.1172/JCI91190. PMID:28650338.
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170:1109–19e10. doi:10.1016/j.cell.2017.08.027. PMID:28886381.
   PubMed Web of Science ®Google Scholar
• Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41:830–842. doi:10.1016/j.immuni.2014.10.017. PMID:25517615.
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36:1668–1674. doi:10.1200/JCO.2017.75.6270. PMID:29283791.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 blockade: have we found the key to unleash the antitumor immune response? Front Immunol. 2017;8:1597. doi:10.3389/fimmu.2017.01597. PMID:29255458.
   PubMed Web of Science ®Google Scholar
• Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2018;29:84–91. doi:10.1093/annonc/mdx755. PMID:29228097.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. doi:10.1056/NEJMoa1504030. PMID:26027431.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–1356. doi:10.1056/NEJMoa1709684. PMID:28889792.
   PubMed Web of Science ®Google Scholar
• Kokolus KM, Zhang Y, Sivik JM, Schmeck C, Zhu J, Repasky EA, Drabick JJ, Schell TD.Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Oncoimmunology. 2018;7:e1405205. doi:10.1080/2162402X.2017.1405205. PMID:29399407.
   PubMed Web of Science ®Google Scholar
• Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, Liu H, Kokolus KM, Eng JW, Messmer MN, et al. beta-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy. Cancer Res. 2017;77:5639–5651. doi:10.1158/0008-5472.CAN-17-0546. PMID:28819022.
   PubMed Web of Science ®Google Scholar
• Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, Geukes Foppen MH, Scolyer R, Song JY, et al. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology. 2016;5:e1238557. doi:10.1080/2162402X.2016.1238557. PMID:28123875.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015;7:279ra41. doi:10.1126/scitranslmed.aaa4691. PMID:25787767.
   PubMed Web of Science ®Google Scholar
• Beutler JA, Jato J, Cragg GM, Boyd MR, Schweinfurthin D. a cytotoxic stilbene from Macaranga schweinfurthii. Nat Prod Lett. 2000;14:399–404. doi:10.1021/np980208m. PMID:9868152.
   Web of Science ®Google Scholar
• Beutler JA, Shoemaker RH, Johnson T, Boyd MR. Cytotoxic geranyl stilbenes from Macaranga schweinfurthii. J Nat Prod. 1998;61:1509–1512. PMID:10.1021/np980208m.
   PubMed Web of Science ®Google Scholar
• Yoder BJ, Cao SG, Norris A, Miller JS, Ratovoson F, Razafitsalama J, Andriantsiferana R, Rasamison VE, Kingston DGI. Antiproliferative prenylated stilbenes and flavonoids from Macaranga alnifolia from the Madagascar rainforest. J Nat Prod. 2007;70:342–346. doi:10.1021/np060484y. PMID:17326683.
   PubMed Web of Science ®Google Scholar
• Turbyville TJ, Gursel DB, Tuskan RG, Walrath JC, Lipschultz CA, Lockett SJ, Wiemer DF, Beutler JA, Reilly KM. Schweinfurthin A selectively inhibits proliferation and rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner. Mol Cancer Ther. 2010;9:1234–1243. doi:10.1158/1535-7163.mct-09-0834. PMID:20442305.
   PubMed Web of Science ®Google Scholar
• Ulrich NC, Kodet JG, Mente NR, Kuder CH, Beutler JA, Hohl RJ, Wiemer DF. Structural analogues of schweinfurthin F: probing the steric, electronic, and hydrophobic properties of the D-ring substructure. Bioorg Med Chem. 2010;18:1676–1683. doi:10.1016/j.bmc.2009.12.063. PMID:20116262.
   PubMed Web of Science ®Google Scholar
• Ulrich NC, Kuder CH, Hohl RJ, Wiemer DF. Biologically active biotin derivatives of schweinfurthin F. Biorg Med Chem Lett. 2010;20:6716–6720. doi:10.1016/j.bmcl.2010.08.143. PMID:20869871.
   PubMed Web of Science ®Google Scholar
• Mente NR, Wiemer AJ, Neighbors JD, Beutler JA, Hohl RJ, Wiemer DF. Total synthesis of (R,R,R)– and (S,S,S)–schweinfurthin F: differences of bioactivity in the enantiomeric series. Biorg Med Chem Lett. 2007;17:911–915. doi:10.1016/j.bmcl.2006.11.096. PMID:17236766.
   PubMed Web of Science ®Google Scholar
• Neighbors JD, Beutler JA, Wiemer DF. Synthesis of nonracemic 3-deoxyschweinfurthin B. J Org Chem. 2005;70:925–931. doi:10.1021/jo048444r. PMID:15675850.
   PubMed Web of Science ®Google Scholar
• Neighbors JD, Buller MJ, Boss KD, Wiemer DF. A concise synthesis of pawhuskin A. J Nat Prod. 2008;71:1949–1952. doi:10.1021/np800351c. PMID: 18922035.
   PubMed Web of Science ®Google Scholar
• Kuder CH, Neighbors JD, Hohl R, Wiemer DF. Synthesis and biological activity of a fluorescent schweinfurthin analogue. Bioorg Med Chem. 2009. doi:10.1016/j.bmc.2009.04.071. PMID:19464190.
   Google Scholar
• Neighbors JD, Mente NR, Boss KD, Zehnder DW, Wiemer DF. Synthesis of the schweinfurthin hexahydroxanthene core through Shi epoxidation. Tetrahedron Letters. 2008;49:516–519. doi:10.1016/j.tetlet.2007.11.086.
   Web of Science ®Google Scholar
• Neighbors JD, Salnikova MS, Beutler JA, Wiemer DF. Synthesis and structure–activity studies of schweinfurthin B analogs: evidence for the importance of a D-ring hydrogen bond donor in expression of differential cytotoxicity. Bioorg Med Chem. 2006;14:1771–1784. doi:10.1016/j.bmc.2005.10.025. PMID:16290161.
   PubMed Web of Science ®Google Scholar
• Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR. Display and analysis of patterns of differential activity of drugs against human-tumor cell-lines: development of mean graph and compare algorithm. J Natl Cancer Inst. 1989;81:1088–1092. PMID:2738938.
   PubMedGoogle Scholar
• Kuder CH, Weivoda MM, Zhang Y, Zhu J, Neighbors JD, Wiemer DF, Hohl RJ. 3-deoxyschweinfurthin B lowers cholesterol levels by decreasing synthesis and increasing export in cultured cancer cell lines. Lipids. 2015:1–13. doi:10.1007/s11745-015-4083-z. PMID:26494560.
   Web of Science ®Google Scholar
• Bietz A, Zhu HY, Xue MM, Xu CQ. Cholesterol metabolism in T cells. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.01664. PMID:29230226.
   PubMed Web of Science ®Google Scholar
• Gruenbacher G, Thurnher M. Mevalonate metabolism in immuno-oncology. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.01714. PMID:29250078.
   PubMed Web of Science ®Google Scholar
• Kodet JG, Beutler JA, Wiemer DF. Synthesis and structure activity relationships of schweinfurthin indoles. Bioorg Med Chem. 2014;22:2542–2552. doi:10.1016/j.bmc.2014.02.043. PMID:24656801.
   PubMedGoogle Scholar
• Stevens JW, Meyerholz DK, Neighbors JD, Morcuende JA. 5ʹ-methylschweinfurthin G reduces chondrosarcoma tumor growth. J Orthop Res. 2017. doi:10.1002/jor.23753. PMID:28960476.
   PubMed Web of Science ®Google Scholar
• Kodet JG, Wiemer DF. Synthesis of indole analogues of the natural schweinfurthins. J Org Chem. 2013;78:9291–9302. doi:10.1021/jo4014244. PMID:24004185.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111. doi:10.1038/nri.2016.107. PMID:27748397.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. doi:10.1146/annurev-immunol-032712-100008. PMID:23157435.
   PubMed Web of Science ®Google Scholar
• Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123:321–334. doi:10.1016/j.cell.2005.08.032. PMID:16239148.
   PubMed Web of Science ®Google Scholar
• Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174:6477–6489. PMID:15879151.
   PubMed Web of Science ®Google Scholar
• Verma MK, Clemens J, Burzenski L, Sampson SB, Brehm MA, Greiner DL, Shultz LD. A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo. J Immunol Methods. 2017;446:47–53. doi:10.1016/j.jim.2017.03.021. PMID:28390927.
   PubMed Web of Science ®Google Scholar
• Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016;21:1230–1240. doi:10.1634/theoncologist.2016-0055. PMID:27401894.
   PubMed Web of Science ®Google Scholar
• Holstein SA, Kuder CH, Tong H, Hohl RJ. Pleiotropic effects of a schweinfurthin on isoprenoid homeostasis. Lipids. 2011;46:907–921. doi:10.1007/s11745-011-3572-y. PMID:21633866.
   PubMed Web of Science ®Google Scholar
• Burgett AWG, Poulsen TB, Wangkanont K, Anderson DR, Kikuchi C, Shimada K, Okubo S, Fortner KC, Mimaki Y, Kuroda M, et al. Natural products reveal cancer cell dependence on oxysterol-binding proteins. Nat Chem Biol. 2011;7:639–647. doi:10.1038/nhembio.625. PMID:21822274.
   PubMed Web of Science ®Google Scholar
• Bao X, Zheng W, Sugi NH, Agarwala Kl, Xu Q, Wang Z, Tendyke K, Lee W, Parent L, Wei L, et al. Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking. Can Biol Ther. 2015;16:1–13. doi:10.1080/15384047.2015.1019184. PMID:25729885.
   PubMed Web of Science ®Google Scholar
• Zhou H, Sauvat A, Gomes-da-Silva LC, Durand S, Forveille S, Iribarren K, Yamazaki T, Souquere S, Bezu L, Muller K, et al. The oncolytic compound LTX-401 targets the Golgi apparatus. Cell Death Differ. 2016;23:2031–2041. doi:10.1038/cdd.2016.86. PMID:27588704.
   PubMed Web of Science ®Google Scholar
• Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, Bosia A, Ghigo D, Massaia M. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. Plos One. 2013;8. doi:10.1371/journal.pone.0060975. PMID:23593363.
   Web of Science ®Google Scholar
• Riganti C, Massaia M. Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells Killing two birds with one stone. Oncoimmunology. 2013;2. doi:10.4161/onci.25770. PMID:24327936.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28:690–714. doi:10.1016/j.ccell.2015.10.012. PMID:26678337.
   PubMed Web of Science ®Google Scholar
• Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, Yamazaki T, Poirier-Colame V, Newton A, Redouane Y, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44:343–354. doi:10.1016/j.immuni.2015.11.024. PMID:26872698.
   PubMed Web of Science ®Google Scholar
• Dosset M, Vargas TR, Lagrange A, Boidot R, Vegran F, Roussey A, Chalmin F, Dondaine L, Paul C, Marie-Joseph EL, et al. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology. 2018;7:e1433981. doi:10.1080/2162402X.2018.1433981. PMID:29872568.
   PubMed Web of Science ®Google Scholar
• Lei A, Yang Q, Li X, Chen H, Shi M, Xiao Q, Cao Y, He Y, Zhou J. Atorvastatin promotes the expansion of myeloid-derived suppressor cells and attenuates murine colitis. Immunology. 2016;149:432–446. doi:10.1111/imm.12662. PMID:27548304.
   PubMed Web of Science ®Google Scholar
• Zamanian-Daryoush M, Lindner DJ, DiDonato JA, Wagner M, Buffa J, Rayman P, Parks JS, Westerterp M, Tall AR, Hazen SL. Myeloid-specific genetic ablation of ATP-binding cassette transporter ABCA1 is protective against cancer. Oncotarget. 2017;8:71965–71980. doi:10.18632/oncotarget.18666. PMID:29069761.
   PubMedGoogle Scholar
• Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, Kurth I, Andreu-Agullo C, Derbyshire ML, Posada J, et al. LXR/ApoE activation restricts innate immune suppression in cancer. Cell. 2018;172:825–40e18. doi:10.1016/j.cell.2017.12.026. PMID:29336888.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Fujita M, Hasegawa H, Arimoto A, Nishi M, Fukuoka E, Sugita Y, Matsuda T, Sumi Y, Suzuki S, et al.Frequency of myeloid-derived suppressor cells in the peripheral blood reflects the status of tumor recurrence. Anticancer Res. 2017;37:3863–3869. doi:10.21873/anticanres.11766. PMID:28668887.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Fujita M, Hasegawa H, Arimoto A, Nishi M, Fukuoka E, Sugita Y, Matsuda T, Sumi Y, Suzuki S, et al. HMG-CoA reductase promotes protein prenylation and therefore is indispensible for T-cell survival. Cell Death Dis. 2017;8:e2824. doi:10.1038/cddis.2017.221. PMID:28542128.
   PubMed Web of Science ®Google Scholar
• Thurnher M, Gruenbacher G. T lymphocyte regulation by mevalonate metabolism. Sci Signal. 2015;8:re4. doi:10.1126/scisignal.2005970. PMID:25829448.
   PubMed Web of Science ®Google Scholar
• Yang W, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X, Meng X, Li L, Wang J, Xu C, et al.  Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature. 2016;531:651–655. doi:10.1038/nature17412. PMID:26982734.
   PubMed Web of Science ®Google Scholar
• Ma X, Bi E, Huang C, Lu Y, Xue G, Guo X, Wang A, Yang M, Qian J, Dong C, et al. Cholesterol negatively regulates IL-9-producing CD8(+) T cell differentiation and antitumor activity. J Exp Med. 2018;215:1555–1569. doi:10.1084/jem.20171576. PMID:29743292.
   PubMed Web of Science ®Google Scholar
• Schell TD, Mylin LM, Georgoff I, Teresky AK, Levine AJ, Tevethia SS. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. J Virol. 1999;73:5981–5993. PMID:10364350.
   PubMed Web of Science ®Google Scholar
• Rose S, Misharin A, Perlman H. A novel Ly6C/Ly6G-based strategy to analyze the mouse splenic myeloid compartment. Cytometry A. 2012;81:343–350. doi:10.1002/cyto.a.22012. PMID:22213571.
   PubMed Web of Science ®Google Scholar